BRAF V600E突变型转移性结直肠癌的分子生物学基础及治疗进展OA
Molecular biology basis and therapeutic advances in BRAF V600E-mutant metastatic colorectal cancer
结直肠癌(colorectal cancer,CRC)是全球高发的恶性肿瘤,晚期患者的预后通常较差.约10%的转移性CRC(metastatic CRC,mCRC)患者携带BRAF V600E突变,该突变通过持续激活丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)信号通路,驱动肿瘤的侵袭和转移,导致患者的中位生存期显著缩短至12～18个月.然而,传统化疗对这类患者的疗效有限.近年来,针对BRAF V600E突变治疗策略的探索逐步深入,多项研究通过靶向治疗、免疫治疗及联合治疗,在改善患者预后方面取得了显著进展.本文综述BRAF V600E突变在mCRC中的分子机制及治疗进展,并重点讨论靶向治疗与免疫治疗联合应用的前景.
Colorectal cancer(CRC)ranks as the common malignancy globally,with advanced-stage patients typically experiencing poor prognoses.Approximately 10%of metastatic CRC(mCRC)patients harbor the BRAF V600E mutation,which drives tumor invasion and metastasis by continuously activating the mitogen-activated protein kinase(MAPK)signaling pathway,leading to a significant reduction in the median survival time to 12-18 months.However,traditional chemotherapy has limited efficacy for these patients.In recent years,therapeutic strategies targeting the BRAF V600E mutation have been progressively explored.Multiple studies have made remarkable progress in improving patient prognosis through targeted therapy,immunotherapy,and their combined regimens.This review summarized the molecular mechanisms and therapeutic advances in BRAF V600E-mutant metastatic colorectal cancer,with a focus on the promising potential of combined targeted-immunotherapy regimens.
周敬杰;洪永刚;刘鹏;蒋慧;尹小兰;郝立强
海军军医大学第一附属医院肛肠外科,上海 200433海军军医大学第一附属医院肛肠外科,上海 200433海军军医大学第一附属医院肛肠外科,上海 200433海军军医大学第一附属医院病理科,上海 200433上海大学附属四一一医院肿瘤中心,上海 200081海军军医大学第一附属医院肛肠外科,上海 200433
医药卫生
结直肠癌BRAF V600E突变分子机制靶向治疗免疫治疗
Colorectal cancerBRAF V600E mutationMolecular mechanismsTargeted therapyImmunotherapy
《中国癌症杂志》 2026 (3)
278-289,12
评论